Tumor-associated antigen levels (Carcinoembryonic antigen, human chorionic gonadotropin, and alpha-fetoprotein) antedating the diagnosis of cancer in the framingham study

Roger R. Williams, K. Robert McIntire, Thomas A. Waldmann, Manning Feinleib, V. L. Go, William B. Kannel, Thomas R. Dawber, William P. Castelli, Patricia M. McNamara

Research output: Contribution to journalArticle

Abstract

Determinations of carcinoembryonic antigen (CEA), human chorionic gonadotropin (HCG), and α-fetoprotein (AFP) were done by use of frozen serum samples antedating the diagnosis of cancer for 9 pancreatic and 8 gastric carcinoma patients from the Framingham Heart Study. The longest intervals for elevated antigens before cancer diagnosis were 10 months for CEA and 26 months for HCG. (The single elevated AFP was found in a sample 10 days before clinical diagnosis.) Samples from 31 controls matched with the cancer subjects by age, sex, vital capacity, and smoking status showed over 20% "false" positive CEA elevations (all smokers with low vital capacities) and over 20% borderline false positive HCG elevations in postmenopausal females. Although 10-26 months’ lead time could infer some potential for use of these tumor-associated antigens to help detect malignant neoplasms at an earlier stage, a serious problem of frequent false positives prevents CEA and HCG levels from being useful as cancer-screening tests at this time.

Original languageEnglish (US)
Pages (from-to)1547-1551
Number of pages5
JournalJournal of the National Cancer Institute
Volume58
Issue number6
DOIs
StatePublished - 1977
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
alpha-Fetoproteins
Neoplasm Antigens
Chorionic Gonadotropin
Fetal Proteins
Vital Capacity
Neoplasms
Pancreatic Neoplasms
Early Detection of Cancer
Stomach
Smoking
Carcinoma
Antigens
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tumor-associated antigen levels (Carcinoembryonic antigen, human chorionic gonadotropin, and alpha-fetoprotein) antedating the diagnosis of cancer in the framingham study. / Williams, Roger R.; McIntire, K. Robert; Waldmann, Thomas A.; Feinleib, Manning; Go, V. L.; Kannel, William B.; Dawber, Thomas R.; Castelli, William P.; McNamara, Patricia M.

In: Journal of the National Cancer Institute, Vol. 58, No. 6, 1977, p. 1547-1551.

Research output: Contribution to journalArticle

Williams, Roger R. ; McIntire, K. Robert ; Waldmann, Thomas A. ; Feinleib, Manning ; Go, V. L. ; Kannel, William B. ; Dawber, Thomas R. ; Castelli, William P. ; McNamara, Patricia M. / Tumor-associated antigen levels (Carcinoembryonic antigen, human chorionic gonadotropin, and alpha-fetoprotein) antedating the diagnosis of cancer in the framingham study. In: Journal of the National Cancer Institute. 1977 ; Vol. 58, No. 6. pp. 1547-1551.
@article{37f05cd5e22347cab323edce8bf14a93,
title = "Tumor-associated antigen levels (Carcinoembryonic antigen, human chorionic gonadotropin, and alpha-fetoprotein) antedating the diagnosis of cancer in the framingham study",
abstract = "Determinations of carcinoembryonic antigen (CEA), human chorionic gonadotropin (HCG), and α-fetoprotein (AFP) were done by use of frozen serum samples antedating the diagnosis of cancer for 9 pancreatic and 8 gastric carcinoma patients from the Framingham Heart Study. The longest intervals for elevated antigens before cancer diagnosis were 10 months for CEA and 26 months for HCG. (The single elevated AFP was found in a sample 10 days before clinical diagnosis.) Samples from 31 controls matched with the cancer subjects by age, sex, vital capacity, and smoking status showed over 20{\%} {"}false{"} positive CEA elevations (all smokers with low vital capacities) and over 20{\%} borderline false positive HCG elevations in postmenopausal females. Although 10-26 months’ lead time could infer some potential for use of these tumor-associated antigens to help detect malignant neoplasms at an earlier stage, a serious problem of frequent false positives prevents CEA and HCG levels from being useful as cancer-screening tests at this time.",
author = "Williams, {Roger R.} and McIntire, {K. Robert} and Waldmann, {Thomas A.} and Manning Feinleib and Go, {V. L.} and Kannel, {William B.} and Dawber, {Thomas R.} and Castelli, {William P.} and McNamara, {Patricia M.}",
year = "1977",
doi = "10.1093/jnci/58.6.1547",
language = "English (US)",
volume = "58",
pages = "1547--1551",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Tumor-associated antigen levels (Carcinoembryonic antigen, human chorionic gonadotropin, and alpha-fetoprotein) antedating the diagnosis of cancer in the framingham study

AU - Williams, Roger R.

AU - McIntire, K. Robert

AU - Waldmann, Thomas A.

AU - Feinleib, Manning

AU - Go, V. L.

AU - Kannel, William B.

AU - Dawber, Thomas R.

AU - Castelli, William P.

AU - McNamara, Patricia M.

PY - 1977

Y1 - 1977

N2 - Determinations of carcinoembryonic antigen (CEA), human chorionic gonadotropin (HCG), and α-fetoprotein (AFP) were done by use of frozen serum samples antedating the diagnosis of cancer for 9 pancreatic and 8 gastric carcinoma patients from the Framingham Heart Study. The longest intervals for elevated antigens before cancer diagnosis were 10 months for CEA and 26 months for HCG. (The single elevated AFP was found in a sample 10 days before clinical diagnosis.) Samples from 31 controls matched with the cancer subjects by age, sex, vital capacity, and smoking status showed over 20% "false" positive CEA elevations (all smokers with low vital capacities) and over 20% borderline false positive HCG elevations in postmenopausal females. Although 10-26 months’ lead time could infer some potential for use of these tumor-associated antigens to help detect malignant neoplasms at an earlier stage, a serious problem of frequent false positives prevents CEA and HCG levels from being useful as cancer-screening tests at this time.

AB - Determinations of carcinoembryonic antigen (CEA), human chorionic gonadotropin (HCG), and α-fetoprotein (AFP) were done by use of frozen serum samples antedating the diagnosis of cancer for 9 pancreatic and 8 gastric carcinoma patients from the Framingham Heart Study. The longest intervals for elevated antigens before cancer diagnosis were 10 months for CEA and 26 months for HCG. (The single elevated AFP was found in a sample 10 days before clinical diagnosis.) Samples from 31 controls matched with the cancer subjects by age, sex, vital capacity, and smoking status showed over 20% "false" positive CEA elevations (all smokers with low vital capacities) and over 20% borderline false positive HCG elevations in postmenopausal females. Although 10-26 months’ lead time could infer some potential for use of these tumor-associated antigens to help detect malignant neoplasms at an earlier stage, a serious problem of frequent false positives prevents CEA and HCG levels from being useful as cancer-screening tests at this time.

UR - http://www.scopus.com/inward/record.url?scp=0017645397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017645397&partnerID=8YFLogxK

U2 - 10.1093/jnci/58.6.1547

DO - 10.1093/jnci/58.6.1547

M3 - Article

C2 - 68118

AN - SCOPUS:0017645397

VL - 58

SP - 1547

EP - 1551

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -